

Audrey's Life Science Meeting Picks for April 10, 2017 – June 2017
Complimentary Service of AudreysNetwork.com
April 10, 2017

Bio2Device Group, Tuesday Evening, April 11, 2017

Topic: "Integrated, Intelligent SmartDermal™ Therapeutics"

Event Date:

Speaker: Patrick Ruane, Ph.D., Senior VP Research and Development, Chrono Therapeutics

Date and Time: Tuesday, April 11, 2017, 6:00 pm

Location: Wilson Sonsini Goodrich & Rosati - 650 Page Mill Road, Palo Alto

Cost:

\$6 - Students/In-transition - Members only

\$11 - Early-bird Registration - Members only

\$20 - Late Registration and Non-Members

\$25 - Walk-ins

Register at www.Bio2DeviceGroup.org

Payment Options April 11th Event

We use PAYPAL to process your online payment. Print and bring a copy of your online receipt with you. If space permits, walk-ins are welcomed; please be prepared to pay \$25 cash or check. There is no refund, exchange, or transfer. Thank you for your cooperation. To register now, select the appropriate registration level and your meal preference from the pull-down menus below and enter the name and email of the attendee. Then click on the "Pay Now" button to reach the PayPal payment page. Each attendee must be registered separately. Please register a non-member by logging out first.

Topic Description

Patrick will describe the technology, the challenges associated with developing this technology (Drug, Medical Device and Technology rolled into a single product) and outline how the technology can be used as a platform for transdermal drug delivery in the treatment of Smoking Cessation, Parkinson's Disease and Opioid Tapering. He will also discuss Regulatory, Clinical and Business strategy if people are interested, and will bring their product along for you to view.

Speaker Bio

Dr. Ruane has nearly 2 decades of experience in drug delivery for combination medical devices. He most recently served as Vice President of R&D at CV Ingenuity (acquired by Covidien) and has held various positions in R&D at Xtent, Cook Group and Navigant Biotechnologies.

Dr. Ruane received his primary degrees in Chemistry from The Galway-Mayo Institute of Technology and Trinity College Dublin, his Ph.D. from University College Dublin and Post-Docs at University of Toronto and The Johns Hopkins University. He is published extensively in both the academic and patent literature.

Chrono Therapeutics (CHRONO) is a pharmaceutical company with a vision of transforming disease and addiction management to become the market leader in programmable passive transdermal drug delivery (TDD) that offers real-time behavioral support. Chrono's executive leadership combines years of professional experience and personal passions for developing life-saving medical products.

CLSA, Tuesday MidDay, April 11, 2017

Event: Lunch & Learn Series: Lunch & Learn - Common Stock Valuations: Myths and Reality

Speakers: Angela Rusakova, Lead Client Service and Audit Partner; *Camron Uhr, Managing Director, Deloitte Transactions and Business Analytics LLP*

Date and Time: Tuesday, April 11, 2017, 11:00am - 2:00pm PT

Registration & Lunch: 11:00 am - 11:30 am

Program: 11:30 am - 12:30 pm

Networking: 12:30 - 1:00pm

Location: CLSA Events Center, 250 E. Grand Ave, Ste 26, South San Francisco, CA 94080

Fee: Member: Complimentary (CLSA Membership will be verified upon registration. To check membership status visit our directory).

Non-Member: \$75

Register at [https://www.eventbrite.com/e/lunch-learn-common-stock-valuations-myths-and-reality-tickets-](https://www.eventbrite.com/e/lunch-learn-common-stock-valuations-myths-and-reality-tickets-32366748817?utm_source=Master+List&utm_campaign=e5491e8771-EMAIL_CAMPAIGN_2017_03_15&utm_medium=email&utm_term=0_a9171f83c7-e5491e8771-196415673)

[32366748817?utm_source=Master+List&utm_campaign=e5491e8771-](https://www.eventbrite.com/e/lunch-learn-common-stock-valuations-myths-and-reality-tickets-32366748817?utm_source=Master+List&utm_campaign=e5491e8771-EMAIL_CAMPAIGN_2017_03_15&utm_medium=email&utm_term=0_a9171f83c7-e5491e8771-196415673)

[EMAIL_CAMPAIGN_2017_03_15&utm_medium=email&utm_term=0_a9171f83c7-e5491e8771-196415673](https://www.eventbrite.com/e/lunch-learn-common-stock-valuations-myths-and-reality-tickets-32366748817?utm_source=Master+List&utm_campaign=e5491e8771-EMAIL_CAMPAIGN_2017_03_15&utm_medium=email&utm_term=0_a9171f83c7-e5491e8771-196415673)

Topic Description

Common Stock Valuations: Myths and Reality

Is your company issuing stock and share-based awards for services to employees, directors and consultants? Then you probably know what a 409a valuation is. But, are you familiar with which valuation methodologies are most appropriate at a particular stage of the company's development? Can you have one valuation methodology for IRS and one for financial reporting purposes? Join us for a lunch to discuss some myths and realities around 409a valuations.

- 409a valuation - when should you prepare one
- 409a vs. US GAAP valuation
- Valuation methodologies
- Fair values of common and preferred stock
- Pre-IPO valuations SPONSORED BY:

[http://califesciences.us2.list-](http://califesciences.us2.list-manage1.com/track/click?u=ac3d0585c9793eba2bcaf4046&id=426f171dad&e=bd3a594c11)

[manage1.com/track/click?u=ac3d0585c9793eba2bcaf4046&id=426f171dad&e=bd3a594c11](http://califesciences.us2.list-manage1.com/track/click?u=ac3d0585c9793eba2bcaf4046&id=426f171dad&e=bd3a594c11)

Deloitte professionals will share their experiences working with start-up life sciences companies and answer your questions about common stock and company valuations. The skills learned during this program will be valuable to you in communications with your boards, IRS, auditors, and bankers throughout your company's life cycle.

Speakers Bios

Angela has over 20 years of experience serving both public and private companies with a focus on the life sciences industry. She works with companies in all stages of growth, from start-ups to SEC registrants. Her technical background includes complex accounting issues such as revenue recognition, equity, derivatives, stock-based compensation, and acquisitions. Angela has been involved in financing and M&A transactions, including initial public offerings, debt and common stock offerings, leveraged buyouts and acquisitions. She has extensive international experience and

is a certified public accountant in the United States and the United Kingdom. Angela also served as a CFO before returning to public accounting in 2003.

Camron M. Uhr is a Managing Director with Deloitte Advisory specializing in business valuation services. Mr. Uhr has thirteen years of experience performing business and asset valuations for advisory and financial reporting purposes. Currently, Mr. Uhr emphasizes in valuations for financial reporting purposes, including: ASC 350 and 805 compliance, 409A and ASC 718 option valuation, and valuations of privately-held common and preferred stock. Additionally, Mr. Uhr also provides audit support services for Deloitte & Touche LLP performing statement of audit support ("SAS") 101 reviews of fair value estimates to be used in the financial statements of Deloitte & Touche LLP audit clients. Prior to joining Deloitte, Mr. Uhr was employed as a Senior Analyst for a boutique investment banking and valuation services firm.

Mr. Uhr holds a Bachelor of Science degree in Business Administration, with an emphasis in Finance, from the University of California, Riverside and a Masters of Business Administration from California State University, Fullerton.

WIB, Wednesday Evening, April 12, 2017

Subject: WIB-National Webinar "Risky Business: Mitigating Risk in the Life Sciences"

Speaker: Gretchen Stup, Sr. Consultant at Latham Biopham Group

Date and Time: April 12, 2017, 1:00 p.m. – 2:00 p.m. EST*

*- Please note this webinar's time is listed in Eastern Standard Time.

Pricing Information

Members: Free

Non-Members: \$30

* - Registrants will be sent a specific GoToMeeting link to access the webinar. Please be sure to click on the link before the webinar to ensure the program is properly installed on your computer.

Register at <http://womeninbio.org/eventdetails.aspx?EventId=30877>

Registration Deadline

April 11, 2017

Registrants will receive a webinar link via confirmation email

Webinar Description

Inviting. Supporting. Succeeding.

All projects present risk, and successful project managers recognize that it is vital not to avoid risks, but to understand them. Risk management is the process of identifying, assessing, mitigating, and controlling the known risks in order to increase the probability of meeting your project objectives. By planning for unexpected events, you can be ready to respond if they arise. This webinar will be led by Gretchen Stup, Senior Consultant, Latham BioPharm Group, and will bring to light the importance of Risk Management as well as introduce methods and tools that can be implemented to ensure a successful risk management process. Gretchen will utilize a slide presentation and will review specific examples to help illustrate the key concepts of Risk Management. The presentation will help you understand how to identify what can go wrong, how to assess a risk events probability and impact, and what to do to lessen the probability or impact of a risk event occurring. Real-world examples and considerations from the speaker's professional experience will be highlighted during the webinar. In addition, there will be time allotted for questions and answers at the conclusion of the webinar.

This course will result in up to one hour of PMI-approvable Professional Development Units (PDUs) for the project management field.
Learn more and register for this event.

Speaker Bio

About Gretchen Stup: Gretchen has over 16 years of experience in the management of government contracts, and over 18 total years of experience working in a scientific environment. She is currently a Sr. Consultant at Latham Biopharm Group where she provides program management and systems integration support to government and client related projects. Prior to this, she served as a Sr. Project Manager for DynPort Vaccine Company (DVC) where she managed a >\$350 M DoD advanced vaccine development contract and a smaller NIAID R&D contract. She has experience in total project lifecycle management, with a focus on managing and integrating the activities of numerous functional areas, including finance, manufacturing, nonclinical, quality, clinical, and regulatory personnel, and managing project related subcontractors. Prior to working in Program Management, Gretchen co-developed and implemented DVC's comprehensive Risk Management program. She has a Bachelor of Science degree from Shepherd University and is a Project Management Professional (PMP) as certified by the Project Management Institute.

Walk-Ins Accepted?

Walk-ins are not accepted – be sure to register early!

Bio2Device Group, Tuesday Morning, April 18, 2017

Topic: "The Digital Health Revolution: Challenges and Opportunities"

Date and Time: Tuesday, April 18, 2017, 8:30 am

Location: Sunnyvale City Council Chambers- 456 West Olive Ave., Sunnyvale

There is no registration or fees for morning meetings.

Topic Description

With \$4B in venture funding last year and over 200,000 medical apps currently available for download, digital health has captured the attention of investors, entrepreneurs, and tech giants across the US. The current digital health landscape includes a broad range of technology solutions that span different applications, from consumer wellness to telemedicine to data analytics. These solutions address healthcare across the entire spectrum, from self-management in the home to ambulatory and hospital care.

Despite growing enthusiasm and consumer adoption of digital health solutions, significant barriers make it difficult for early stage digital health companies to scale effectively or reach profitability. These barriers include physician and patient adoption, a lack of data to substantiate improved health outcomes and cost savings, limited integration into clinical workflows and EHRs, reimbursement challenges, and regulatory hurdles. A complex, fragmented healthcare system that continues to struggle with interoperability further magnifies these barriers.

Where will digital health solutions have the greatest impact? How can companies address these barriers to accelerate adoption? In what ways can stakeholders better coordinate their efforts within the digital health ecosystem? Using stories and examples, this session will dig deeper into the largest opportunities and hardest challenges that digital health will face in the future.

Speaker Bio

Anne Merritt, MD, is an academic physician and healthcare consultant with over ten years of experience in healthcare technology, patient safety, and quality improvement. She is currently a Clinical Instructor in Emergency Medicine at Stanford University. As a physician leader, she has developed strategies to engage physicians in professional development and managed cross-functional teams to improve health outcomes and the patient experience. She has also been an invited speaker at national medical conferences. In addition to her clinical work, she works with Life Science Angels, a premier angel investment group focused on biotech, digital health, medical devices, and diagnostics. She also works as a consultant and advisor to digital health and medical device companies. She earned her medical degree from Yale University and her business degree from Stanford Graduate School of Business.

JLABS, Tuesday Morning, April 18, 2017

Topic: "Meet with the Gates Foundation"

Speaker: Charlotte Hubbert, PhD | Partner, Gates Foundation Venture Capital

Location: JLABS @ SSF, 329 Oyster Point Blvd - 3rd Floor, South San Francisco, California

Date and Time: Tuesday, April 18, 2017, 10:30 am

Agenda:

10:30am | Registration & Networking

11:00am | Company Presentation and Q&A

11:45am | Lunch & Networking

12:45-5:00pm | One-on-one Meetings*

*Companies must have apply ahead of time and be approved for a one-on-one meeting. Application period ends March, 13, 2017. Apply Here.

Fees:

Presentation

\$25 | General Public

\$35 | Onsite

Includes presentation, Q&A, and lunch. All attendees must pay this fee, regardless of one-on-one meeting status. Pre-registration to attend the presentation, Q&A, and lunch will remain open until 12:30pm on April 18th (or sold out).

One-on-One Meeting

FREE | Application

FREE | Accepted Companies

Companies must have applied for a one-on-one meeting ahead of time. The one-on-one application period will close on March 13, 2017. Your application will be reviewed and you will be notified of acceptance by March 30, 2017. Acceptance of one-on-one meeting is not guaranteed as all applications must be approved

Registration at <https://www.eventbrite.com/e/meet-with-the-gates-foundation-tickets-29533732188?aff=weekly>

Program Overview:

The path out of poverty is paved with access to quality healthcare. Do you have solutions that will make a difference? The Bill & Melinda Gates Foundation is advancing science and technology to save lives in developing countries. The Foundation works with partners to deliver proven tools—including vaccines, drugs,

and diagnostics—and discover ground breaking new solutions that are affordable and reliable. Focus areas for investments center on infectious diseases including HIV, polio, TB, dengue and malaria, as well as diagnostics and health IT ideas that bring health interventions to people who need them most.

Charlotte Hubbert, Partner with Gates Foundation Venture Capital, will be in attendance to provide an overview presentation on the Foundation's key areas of interest and venture investment philosophy. Gates Foundation Venture Capital operates under the Program Related Investments group at the Bill & Melinda Gates foundation, which manages a \$1.5B allocation for private sector investment. Charlotte will be on hand to meet with a handful of applicants one-on-one after the presentation. To be considered for a one-on-one meeting complete the information required at the link below.

Speaker Bio

Charlotte Hubbert is a Partner with Gates Foundation Venture Capital, investing innovative technologies that support The Bill & Melinda Gates Foundation initiatives in Global Health and Agriculture. Prior to joining the Gates Foundation, Charlotte was a Vice-President at H.I.G. BioVentures focusing on investment opportunities in the life sciences, including therapeutics, diagnostics and medical devices at all stages of development. She was BOD observer at Cardeas Pharma and Alder Biopharmaceuticals. Charlotte started her career in early stage biotech investing at Accelerator Corporation, an investment vehicle focused on identifying, evaluating, financing and managing emerging therapeutic technologies. During her tenure, Charlotte was involved in the strategic development and management of five companies, including Oncofactor, Groove Biopharma, Acylin Therapeutics, Xori and Pharmselex. Charlotte currently serves as an observer on the board of directors of Synlogic, Sera Prognostics and Lodo Therapeutics.

Charlotte earned a B.S. in Microbiology from the University of Washington and a Ph.D. in Pharmacology and Cancer Biology from Duke University. She did her post-doctoral work in stemcells and regenerative medicine at the Institute for Stem Cells and Regenerative Medicine at the University of Washington. Charlotte is a member of the Kauffman Society of Fellows (Class 14).

Connect with Charlotte: [Connect on LinkedIn](#)

About the Meet with... Series:

The purpose of the Meet with Series events sponsored by JLABS is to help start-up entrepreneurs, as well as the academic community, connect with potential partners, such as big pharma or other investment corporations, through one-on-one meetings. It is also a chance for the featured corporation to outline their specific business development goals and clarify what types of products or research they are interested in and how best to approach them to get the partnering process started. Past participants include the Wellcome Trust, Bill & Melinda Gates Foundation, MedImmune Ventures, Mercury Fund, DARPA's Biological Technologies Office, Correlation Ventures, Breakout Labs, New Enterprise Associates, Canaan Partners, Thomas McNerney & Partners, NCI, NCATS, NINDS, Allegory Venture Partners, Clarus Ventures, Johnson & Johnson Innovation, California Institute for Regenerative Medicine, Astellas Venture Management, and OrbiMed.



BioPharma Consortium, Wednesday Evening, April 19, 2017

Event: 2017 Bi-Annual Networking Mixer
Date and Time: Wednesday, April 19, 2017, 6:00-8:30 PM
Location: Porterhouse Restaurant, 60 E. Third Ave, San Mateo, CA
Pricing: \$20, Early Bird Registration by noon, Friday April 14
 \$25, Pre-Registration by midnight, Tuesday April 18
 \$30 walk-in (cash only)
Register: <http://BPC2017AprEvent.eventzilla.net>

Event Description

Spring Into The Season With Biopharma Consortium!

How did YOUR Q1 of 2017 stack up? What’s really in store for biotech beyond the “Trump bump”? Funding and exit trends in 2017? Will we see a spike in accelerated FDA approvals? Implications of the 21st Century Cures Act? Where will the EMA end up after Brexit? Where do we see drug development, digital health, and precision medicine converging to solve problems and will there be real value delivered to patients?

If it’s leading edge in biotech, we’re talking about it at BPC. Join us for drinks, apps and great conversation. Bring your business card to raffle!
We’ll see you in the bar & lounge over drinks & appetizers. Cash bar.

.....
BioPharma Consortium, Wednesday Evening, April 19, 2017

Event: 2017 Bi-Annual Networking Mixer
Date and Time: Wednesday, April 19, 2017, 6:00-8:30 PM
Location: Porterhouse Restaurant, 60 E. Third Ave, San Mateo, CA
Pricing: \$20, Early Bird Registration by noon, Friday April 14
 \$25, Pre-Registration by midnight, Tuesday April 18
 \$30 walk-in (cash only)
Register: <http://BPC2017AprEvent.eventzilla.net>

Event Description

Spring Into The Season With Biopharma Consortium!

How did YOUR Q1 of 2017 stack up? What’s really in store for biotech beyond the “Trump bump”? Funding and exit trends in 2017? Will we see a spike in accelerated FDA approvals? Implications of the 21st Century Cures Act? Where will the EMA end up after Brexit? Where do we see drug development, digital health, and precision medicine converging to solve problems and will there be real value delivered to patients?

If it’s leading edge in biotech, we’re talking about it at BPC. Join us for drinks, apps and great conversation. Bring your business card to raffle!
We’ll see you in the bar & lounge over drinks & appetizers. Cash bar.

.....
EMBS, Wednesday Evening, April 19, 2017

Topic: “Study of Fluorescence Spectroscopy Guided Optical Biopsy Needle for Prostate Cancer Diagnosis”

Speaker: Amir Tehrani, Chief Executive Officer Precision Biopsy, LLC

Date and Time: Wednesday, April 19, 2017, 7:30 PM

Location: Room M-114, Stanford University Medical School
<http://maps.stanford.edu/sites/all/ibre-shared/files/maps/files/shared/f...>

Parking is usually free after 5 PM at Roth Way Garage, which is at the corner of Roth Way and Campus Drive West (E-7) on the map. The Stanford Hospital Cafeteria is near the Emergency entrance, at D-6 on the map. The Medical School is across Campus Drive West from Roth Way Garage, and Room M114 is accessible from outside the building at E-6 on the map.

Optional dinner location: Stanford Hospital cafeteria, 6:15 PM (no host, no reservations, self-serve)

Topic Description

Current prostate biopsy cores have a very low diagnostic yield. These biopsies often fail to diagnose prostate cancer since 90% of cores are histopathologically classified as benign. The concentrations of endogenous fluorophores in prostate tissue vary with disease states. Thus, fluorescence spectroscopy could be utilized to quantify these variations for identification of malignant lesions. We investigated clinical feasibility of a 14 gauge (1.98 mm) optical biopsy needle guided by fluorescence spectroscopy for real-time in vivo prostate cancer diagnosis. Built-in optical sensor has 8x100µm fibers for tissue excitation and a single 200µm fiber to collect spectral data. Custom-made fluorometer has 2 light-emitting diodes at 290 and 340 nm and a spectrometer. User interface for fluorometer operation and data collection was developed using LabView software. Each spectral data acquisition required ~2 seconds. The in vivo biopsies were performed during radical retropubic prostatectomy surgery on the exposed prostate with blood flow to the gland intact. A tissue biopsy core was obtained from each biopsy site after acquisition of spectral data. Above procedure was repeated ex vivo after surgical excision of the prostate. Biopsy cores were histopathologically classified as either benign or malignant and correlated with corresponding spectral data. Partial Least Square analysis was performed to determine diagnostically significant principal components as potential classifiers. A linear support vector machine and leave-one-out cross validation method was employed for tissue classification. Thirteen patients were consented to the study. Histopathological analysis found cancer in 29/208 in vivo and 51/224 ex vivo viable biopsy cores. Study results show 72% sensitivity, 66% specificity, and 93% negative predictive value for in vivo and 75%, 80%, and 93%, respectively, for ex vivo malignant versus benign prostatic tissue classification. Optical biopsy needle has a very high negative predictive value to indicate benign tissue while sufficient sensitivity for targeting areas suspicious for cancer within the prostate gland. Hence, the optical biopsy needle can increase the diagnostic yield of prostate biopsies with consequent improvement in patient care.

Speaker Bio

Precision Biopsy is led by CEO Amir Tehrani, who has over 20 years' of experience in management and operations, strategy, business development, marketing, design and development for Fortune 500 and start-up medical device companies. Prior to Precision Biopsy, Amir was the President and CEO of Amaranth Medical, Inc., a bioabsorbable stent company. He has been instrumental in the formation and financing of several medical device companies, including Inspiration Medical, Inc., Corventis, Inc. (acquired by Medtronic, Inc.), Spinal Modulation, Inc., (acquired by St. Jude Medical), Sonitus Medical, Inc., and RODO Medical, Inc. Amir also led successful investments and acquisition in the medical technology sector at Guidant Compass Group. He also held several leading marketing and engineering positions at Guidant Vascular Intervention, St. Jude Medical CRM Division, Ventritex, Inc., (acquired by St. Jude Medical), and MiniMed, Inc. (acquired by Medtronic, Inc.). Amir holds a BS in Electrical Engineering from the University of Idaho and an MS in Biomedical Engineering from California State University in Sacramento, CA.

PBSS Symposium, Monday, April 24, 2017

Topic: "Mechanistic Drug Metabolism for Drug Candidate Optimization – A Mini-symposium for Medicinal Chemists and DMPK Scientists"

Organizers: Cyrus Khojasteh and Donglu Zhang (Genentech)

Date and Time: April 24, 2017, 8:45-17:00

Location: Crowne Plaza, Foster City, CA

Registration fee (USD): Minisymposium fee: \$195;

Registration: <http://www.PBSS.org>

Registration deadline: 4/20/2017 (it will close sooner if the seating cap is reached)

Topic Description

Drug metabolism and pharmacokinetics (DMPK) plays an integral role in drug discovery. At drug discovery stage, mechanistic drug metabolism studies contribute to generating drug candidates with optimal ADME properties and in some cases it allows for overcome potential drug development obstacles such as toxicity and DDI that are often encountered in drug discovery and development. In this one-day symposium, multiple examples will be presented to illustrate the utilities of mechanistic drug metabolism in moving discovery and development programs forward. Medicinal chemists and drug metabolism scientists should greatly be benefited from participating in this symposium.

Tentative topics and speakers:

Morning: 8:45-12:00

Overview on drug metabolism and its role in lead optimization - Cyrus Khojasteh, Genentech

Hepatocyte spheroid models and applications in drug metabolism - Jinping Gan, BMS
Sponsor presentation

Drug metabolism tools to assess bioactivation potential of drug candidates - minimizing metabolism-related DILI or genotoxicity - Zhoupeng Zhang, Merck

Prediction of circulating drug metabolites - Ming Hu, University of Houston

Afternoon: 1:15-5:00

Inhibition of endogenous metabolic pathways leading to toxicities - Donglu Zhang, Genentech

Sponsor presentation

Discovery of Bioavailable Pim Inhibitors by Mitigating Intestinal Metabolism – Gina Wang, Genentech

Metabolism-based structure-activity relationship analysis for identification of a PI3K inhibitor clinical candidate devoid off target hepatotoxicity - Raju Subramanian, Gilead

Minimizing reversible and time-dependent CYP inhibition of NAMPT (nicotinamide phosphoribosyltransferase) inhibitors - Mark Zak, Genentech

Carboxylic acid bioactivation via glucuronides/acyl CoA's and application in drug discovery – Mark Grillo, Amgen

..... AWIS, March for Science, Saturday, April 22, 2017

Date and Time: Saturday, April 22, 2017, 10:30 am

Location: Justin Herman Plaza, San Francisco

Fees:

Registration only - Free; Registration + T-shirt - \$25

Details and registration at <http://www.brownpapertickets.com/event/2929650>

Event Description

The March for Science - San Francisco celebrates public discovery, understanding, and distribution of scientific knowledge as crucial to the freedom, success, health, and safety of life on this planet. Join us as we walk in support of Communication, Funding, Policy, Literacy, and Diversity.

WIB, Thursday Evening, April 27, 2017

Topic: "Hot Trends in Personalized Medicine"

Panel: Moderator, Amy Swanson, Illumina; Jackie Benson, J&J Innovations;

Tara Maddala, Grail; Kristin McDonald Gibson, Invitae; Pam Garzone, Pfizer

Date and Time: Thursday, April 27, 2017, 5:30 p.m. – 8:00 p.m. PST

Location: Illumina, 499 Illinois St., San Francisco, CA 94158

Cost: Members - \$20 and nonmembers - \$50

Details and registration at <http://womeninbio.org/eventdetails.aspx?EventId=31271>

Event Description

Rapid advances in sequencing and genomics have resulted in greater access to genomic data collection and analysis. With costs decreasing and speed of sequencing increasing, genomic data can be efficiently interpreted and applied to treat and prevent disease in a practical setting. Removing the barriers between benchtop and bedside enables researchers and physicians to capitalize on these technological advances and deliver high quality personalized health care.

Join us for an insightful panel discussion that will touch on several facets of personalized medicine, including targeted therapeutics, immunology, liquid biopsy, and genetic testing. The panel will be moderated by Amy Swanson, Illumina, and feature the following:

Jackie Benson, J&J Innovations

Tara Maddala, Grail

Kristin McDonald Gibson, Invitae

Pam Garzone, Pfizer

Learn more and register for this event.

Registration Deadline

April 26, 2017

Event Sponsor

<https://www.illumina.com/>

Address:

SanFrancisco@WomenInBio.org

[https://www.linkedin.com/groups/Women-In-Bio-San-Francisco-](https://www.linkedin.com/groups/Women-In-Bio-San-Francisco-4433988?gid=4433988)

[4433988?gid=4433988https://twitter.com/SFWomenInBiohttps://www.facebook.com](https://twitter.com/SFWomenInBio)

[/WomenInBioSF?ref=br_rs](https://www.facebook.com/WomenInBioSF?ref=br_rs)

JLABS Bay Area, Tuesday Mid Day, May 2, 2017

Topic: "Money Matters - Insider Tips on Raising Money"
Speaker: Julie Papanek, Partner, Canaan Partners
Date and Time: Tuesday, May 2, 2017, 10:30 am - 1:00 pm

Agenda:
10:30 AM | Registration and Networking
11:00 AM | Presentation
11:30 AM | Q&A
12:00 PM | Food and Networking
1:00 PM | Program Close

Fees:
\$25 | General Public
\$15 | Student
\$45 | At the door

Location: JLABS @ SSF, 329 Oyster Point Blvd - 3rd Floor, South San Francisco, California

Order at <https://www.eventbrite.com/e/money-matters-insider-tips-on-raising-money-tickets-32167293240?aff=weekly>

Speakers Bio

Julie Papanek is a Partner at Canaan Partners where she concentrates on biopharmaceutical, digital health and consumer medical device investments. Julie currently sits on the board of Protagonist Therapeutics (PTGX) and has also worked closely with and observed on the boards of CytomX, Labrys Biologics, Dermira, ALDEA Pharmaceuticals, Chrono Therapeutics, and Glooko. Prior to Canaan, Julie worked at Genentech in a variety of positions spanning marketing, development, and business development.

Julie earned her MBA from Stanford's Graduate School of Business, MPhil from Cambridge in BioScience Enterprise and B.S. from Yale in Molecular Biophysics and Biochemistry.

QB3, Late Thursday Afternoon, May 11, 2017

Topic: "Leadership in Biopharma: a Conversation with John Milligan, CEO of Gilead Sciences"

Speakers: John Milligan, CEO, Gilead Sciences; Harold E. "Barry" Selick, Ph.D. CEO, Threshold; Brook Byers, Founding Partner of Kleiner Perkins Caufield & Byers

Date and Time: Thursday Afternoon, May 11, 2017, 4:00 - 6:30 pm

Agenda
4:00 pm Introduction: Brook Byers, Partner, Kleiner Perkins Caufield & Byers
4:00-5:00 pm Remarks from John Milligan, Gilead Sciences, followed by audience Q&A and a conversation moderated by Barry Selick, Threshold Pharmaceuticals
5:00-6:30 pm Reception

Location: Byers Auditorium, Genentech Hall, Byers Auditorium, Genentech Hall, UCSF Mission Bay, 600 16th Street. San Francisco, CA 94158

4:00 to 5:00 pm, Thursday, May 11. Reception to follow

Registration is free. Register at https://www.eventbrite.com/e/leadership-in-biopharma-a-conversation-with-john-milligan-ceo-gilead-sciences-tickets-32902967662?mc_eid=cb4c38a44a&mc_cid=c37eecb250#tickets

Background

Gilead Sciences is a Bay Area titan, a life science leader known for its pipeline of antivirals and Hepatitis C therapeutics. Its CEO is John F. Milligan, PhD, a former UCSF postdoc, who joined the company in 1990 as its 32nd employee. Join us on May 11 when Barry Selick, CEO of Threshold Pharmaceuticals and himself a former UCSF postdoc, will engage Milligan in a conversation touching on topics such as Milligan's career path from postdoc to CEO of a major biotech, his experience leading it, and how Gilead feeds its pipeline of innovation and develops new products.

Brook Byers, a Founding Partner of Kleiner Perkins Caufield & Byers and a member of the UCSF Board of Overseers, will provide introductory remarks.

Speaker Bio

Dr. John F. Milligan joined Gilead Sciences in 1990 and was appointed Chief Executive Officer in March 2016. He began his career at Gilead as a research scientist, and subsequently held leadership positions in project management and corporate development before being named Chief Financial Officer in 2002. He was appointed Chief Operating Officer in 2007 and President in 2008.

During his tenure at Gilead, Dr. Milligan has led teams that have developed, manufactured and commercialized more than 20 new therapies for significant unmet needs. He has managed multiple transformative acquisitions, licensing agreements and financings, helping the company grow into a worldwide organization reaching more than 10 million patients. He is a member of the board of Pacific Biosciences of California, Inc. and a Trustee of Ohio Wesleyan University.

Harold E. "Barry" Selick, Ph.D. joined Threshold as Chief Executive Officer in June 2002. Between June 2002 and July 2007, Dr. Selick was also a Venture Partner of Sofinnova Ventures, Inc., a venture capital firm. From January 1999 to April 2002, he was Chief Executive Officer of Camitro Corporation, a biotechnology company that was acquired by ArQule. From 1992 to 1999, he was at Affymax Research Institute, the drug discovery technology development center for Glaxo Wellcome plc, most recently as Vice President of Research. Prior to working at Affymax he held scientific positions at Protein Design Labs, Inc. and Anergen, Inc. As a staff scientist at Protein Design Labs, he co-invented the technology underlying the creation of fully humanized antibody therapeutics and applied that to PDL's first product, Zenapax, which was developed and commercialized by Roche for the prevention of kidney transplant rejection. Dr. Selick received his B.S. and Ph.D. from the University of Pennsylvania and was a Damon Runyon-Walter Winchell Cancer Fund Fellow and an American Cancer Society Senior Fellow at the University of California, San Francisco.

Brook Byers is a Founding Partner of Kleiner Perkins Caufield & Byers. A venture capital investor since 1972, Brook has been closely involved with more than 60 new technology-based ventures, many of which have become public companies. He formed the first life sciences practice group in the venture capital profession in 1984 and led KPCB to become a premier venture capital firm in the medical, healthcare and biotechnology sectors. KPCB has invested in and helped build more than 170 life sciences companies that have developed hundreds of products to treat underserved medical needs for many millions of patients. Brook was the founding president and then chairman of four biotechnology companies that were incubated in KPCB's offices and went on to become public companies with an aggregate market value of more than US\$8 billion. He serves on the board of directors of Cell Design Labs, Enjoy,

Newsela and Zephyr Health. Brook is also a Lifetime Director on the UCSF Board of Overseers.

.....
BioPharma PM Conference, Monday-Tuesday, May 22-24, 2017

Event: Stepping Up and Stepping Out

Dates: Monday, Tuesday and Wednesday, May 22-24, 2017

Program:

May 22

5:00-7:00PM: Registration and Opening Networking Reception

May 23

7:30-9:00AM: Registration and Breakfast Networking

9:00AM-5:00PM: Conference Presentations, Panels, Workshops

5:00-7:00PM: Evening Networking Reception

May 24

7:30-9:00AM: Breakfast Networking

9:00AM-2:30PM: Conference Presentation, Panels, Workshops

2:30PM: Conference Conclusion

Location: San Mateo Marriott San Francisco Airport, 1770 South Amphlett Boulevard, San Mateo, CA 94402

Registration: Early Bird Registration (through March 31): \$695 (plus payment processing fees); Regular Conference Registration (after March 17): \$895 (plus payment processing fees); All registrants will receive a complimentary one-year BioPharmaPM Network membership (a \$50 value).

Register at <https://www.eventbrite.com/e/2017-biopharmapm-conference-tickets-31937261208>

Event Description

Please join us for the 2017 BioPharmaPM Network Conference! We are planning an exciting program for you. Below are a few of our featured speakers, panelists, and trainers who will speak on diverse topics such as managing your career in alignment with your values, leadership development in project management, and how you can solve problems inhibiting project success easily and effectively.

Speakers: William Schiemann, Founder and CEO of Metrus Group and Author; Jean Lee, Ph.D., Vice President, Portfolio and Project Management at Pfizer Global Product Development; Michael Young, Chief Learning Officer and SVP of Education at the The Medicines Company; Mark Velligan, Senior Director of Portfolio Management and Operations at Genentech; Trevi Wormley, Managing Director and Chief Solution Engineer at TJ Strategy Group, LLC

We hope you will join us at the San Mateo Marriot in San Francisco May 22-24 and be a part of the only non-profit organization solely committed to project management best practices, development, and networking for biopharma project and program managers.

FAQs

How can I contact the organizer with any questions?

For questions, please contact Kelly Magnuson at kmagnuson@biopharmapm.org

How do I make room reservations?

We are holding a few rooms at a discounted rate with the San Mateo Marriott. If you require a room, please email Kelly Magnuson at kmagnuson@biopharmapm.org for details.

.....

Bio2Device Group, Tuesday Morning, May 25, 2017

Topic: "A Clinical Trial Roadmap: Who, What, When, and How – Practices, Perspectives and Personal Insights"

Speaker: David Larwood, CEO, Valley Fever Solutions

Date and Time: Tuesday, April 25, 8:30 am

Location: Sunnyvale City Council Chambers- 456 West Olive Ave., Sunnyvale

Topic Details

While many of us conceptually understand the clinical trial process, a deeper dive will provide essential information regarding the parties involved, the risks, structuring and optimizing clinical architecture, design, efficiency, visibility, and more. What are the recommended practices? What is Just-inTime Monitoring? How should you manage your supply chain? How do you select the best CRO? The key is to understand the elements and thus ensure smooth navigation throughout the complex clinical trial landscape and journey. There are a myriad of drugs in clinical trials, each with a story to tell.

Valley Fever Solutions' (VFS) first-in-class compound, Nikkomycin Z (NikZ) is being developed as a dramatically superior potential cure for Valley Fever (VF), a painful and debilitating orphan disease. Collectively, the market for antifungals across a spectrum of similar disease organisms approaches \$1B. Broadly and worldwide, the market reaches \$6B. With Orphan Product designation, NikZ's Phase I trial results have been very promising, and VFS has a "fast track" plan to proof of concept in 10 months. They anticipate showing human efficacy working with an existing trial at the NIH. VFS expects to be a good candidate for an additional \$1.5M FDA orphan drug product trial grant in 2017. Join us and learn from a true expert's professional and personal journey.

Speaker Bio

David Larwood has been a chemist for decades, most recently leading Valley Fever Solutions since 2007 as its CEO. His PhD research at UC San Francisco included the world's first PEGylated liposomes, later leading to Doxil. He was the first to make suitable PEGylated lipids. Earlier, at UC San Diego, he was the first ever to make Iotrolan, a contrast agent still in commercial use 37 years later.

Valley Fever Solutions is a small startup working first on a new and improved treatment for Valley Fever (coccidioidomycosis). Since securing grant support to continue with Phase II trials, Mr. Larwood has been leading improving the API manufacturing process, working on drug product, planning for clinical trials, and organizing the trials.

Mr. Larwood moved away from being a bench scientist when he took a law degree. He advised well known companies on patent matters until he moved to a position at Apple Computer for four years. He took an executive role at a startup, again in an IP role. He then moved to another startup taking Verisity Design public as General Counsel, continuing in that role through a successful acquisition in 2005. David also received an MBA in entrepreneurship from UC Berkeley and Columbia University.

Mr. Larwood is the third of his family to be involved in Valley Fever. His father is a clinician who developed an interest in the disease decades ago when the family moved to Bakersfield, California, a hot spot for Valley Fever. His mother started a foundation in about 1998 and raised some \$20M for research into vaccines for Valley Fever. Her chief scientist was the program manager at Shaman running the Nikkomycin Z drug development project. Timing was perfect for Mr. Larwood to join Valley Fever Solutions in 2007 to drive that project forward.

JLABS, Tuesday Morning, May 23, 2017

Topic: "Rough seas or smooth sailing? Navigating Collaboration Agreements"

Speakers:

Angela Rusakova | Lead Client Service and Audit Partner, Deloitte & Touche LLP

Yelda Kaya | Sr. Director Transactions, Johnson & Johnson Innovation

William J. Newell | CEO, Sutro Biopharma

Moderator: Lesley Stolz | Head of JLABS, CA, Johnson & Johnson Innovation, JLABS

Date and Time: Tuesday, May 23, 2017 from 9:00 AM to 11:30 AM (PDT)

Agenda:

9:00 AM | Registration, Breakfast, and Networking

9:30 AM | Components of a collaboration agreement

10:00 AM | Panel Discussion: Implications of Components

11:00 AM | Q&A

11:30 AM | Program Close

Location: JLABS @ SSF, 329 Oyster Point Blvd - 3rd Floor, South San Francisco, California

Fees:

\$25 | General Public

\$15 | Student

Order at <https://www.eventbrite.com/e/rough-seas-or-smooth-sailing-navigating-collaboration-agreements-tickets-32071988180?aff=weekly>

Event Details

How do you develop a smart collaboration agreement? An effectively written collaboration agreement builds and strengthens a productive scientific relationship by allowing parties to enter into a mutually beneficial relationship.

How do you make sure the agreement will fit your company objectives? An effective agreement should be clear, to both the research workers and managers of both parties, laying the groundwork for moving the results of research toward commercialization. It addresses the nature of the collaboration, the responsibilities and obligations of each party, the desired outcomes and next steps beyond the currently contemplated research.

At this event, we will walk through building components of a collaboration agreement, point out and discuss key terms and provisions that help make a quality agreement. The talk will provide real world examples and focus on the following topics:

Intro to Collaboration Agreements / General provisions

Statement of objectives/work

Budget

IP

Restrictions and opportunities created by agreements

Real world examples from panel members

The panel members will share real life experiences through the R&D collaboration process and beyond. The workshop will examine key types of provisions and their effects on future development and funding opportunities. This "how to" workshop is geared towards life sciences startup

Guests will be provided supporting materials including:

Key provisions guide

Sample Collaboration agreements

This event is being hosted in conjunction with Deloitte. Deloitte is deeply committed to the life sciences industry. As an advisor to many leading health care and life sciences organizations, Deloitte has been instrumental in developing and implementing many strategies that helped shape the evolution and long-term success of this industry. At Deloitte, we serve from early-stage companies to the world's largest players. We know where you go and we can help you to realize your dreams. As with all our events, the "How to...Workshop" is informal and interactive so bring your questions with you!

Speakers' Biographies:

Angela Rusakova | Lead Client Service and Audit Partner, Deloitte & Touche LLP
Angela has 20 years of experience serving both public and private companies with a focus on the life sciences industry. She works with companies in all stages of growth, from start-ups to SEC registrants. Her technical background includes complex accounting issues such as revenue recognition, equity, derivatives, stock-based compensation, and acquisitions. Angela has been involved in financing and M&A transactions, including initial public offerings, offerings in leveraged buyouts, and several secondary shares offerings. She has extensive international experience and is a certified public accountant in the United States and the United Kingdom. Angela also served as a CFO before returning to public accounting in 2003.

Yelda Kaya | Sr. Director Transactions, Johnson & Johnson Innovation
Yelda is the Senior Director of Transactions in Johnson & Johnson Innovation Center, California.

Leveraging a diverse career practicing emergency medicine, corporate law and business development, Yelda brings extensive experience to transactions delivering a unique breadth of deals across sectors with an established track record of successfully leading, structuring, negotiating and executing complex deals over the last 10 years.

Yelda joined the Johnson & Johnson family from GSK's worldwide business development group. She holds a MBBS, LLB and MBA from the University of Melbourne.

William J. Newell | CEO, Sutro Biopharma

Mr. Newell has over 24 years of senior management experience in the biotechnology industry. He joined Sutro Biopharma as CEO in January 2009. Previously, he served as the President of Aerovance, Inc., a venture-backed company developing clinical assets for respiratory diseases. Mr. Newell also was Chief Business Officer and Senior Vice President at publicly-traded QLT, Inc. and served in several senior management positions at public-traded Axys Pharmaceuticals, Inc. For the 16 years prior to joining Axys, Mr. Newell practiced corporate law in the San Francisco Bay Area. He is presently a member of the Board at Symic Bio. Mr. Newell is also a Board member on BIO's Emerging Companies Section and a member of the Board and of the Executive Committee of the California Life Sciences Association.

Lesley Stolz | Head of JLABS, CA, Johnson & Johnson Innovation, JLABS

Dr. Stolz has 20 years of business and corporate development experience working for companies that have been both technology platform and therapeutics focused. After two years negotiating partnering deals for Johnson & Johnson Innovation at the California Innovation Center, Lesley joined the JLABS team as Head of JLABS, CA, to participate in the mission of helping to catalyze new companies in the healthcare

ecosystem. Prior to joining Johnson & Johnson Innovation, she held executive positions with BioTime, Inc., Sutro Biopharma, Inc., and Sunesis Pharmaceuticals where she was responsible for corporate strategy, fundraising and all aspects of partnering. Earlier in her career, she served as Senior Director, Business Development for Aerovance, Inc. and for GPC Biotech AG in Munich, Germany from 2002 to 2006. She also served in senior management positions at Cell Genesys, Discovery Partners International and Axys Pharmaceuticals. During her career she has work on over 45 collaboration agreements helping shape effective opportunities for early stage companies. Dr. Stolz received her Ph.D. in chemistry, and conducted postdoctoral research at Harvard Medical School's Department of Biochemistry and Molecular Pharmacology.

PBSS Minisymposium, Friday, June 2, 2017

Event: Drug-Induced Liver injury (DILI): risk assessment in drug discovery and clinical development

Speakers: William Treem (J&J), Michael Rothenberg (Genentech), Weida Tong (NCTR/FDA), Yazen Alnouti (UNMC), Donna Dambach (Genentech), Cyrus Khojasteh (Genentech), Kenneth Brouwer (Qualyst), Gary Peltz (Stanford Medical)

Date and Time: Friday, June 2, 2017, 9:00 -16:00

Location: Crowne Plaza, Foster City, CA

Registration fee (USD): Regular: \$195; Academic: \$125; Students & Unemployed: \$35;

Registration: <http://www.PBSS.org>

Further Information:

Registration deadline: 5/31/2017 (it will close sooner if the seating cap is reached)

Topic Description

Drug-induced liver injury (DILI) continues to be a leading cause of attrition during small molecule drug development, withdrawal post-marketing, and cautionary / restrictive labeling. Hepatotoxicity risk is difficult to predict based on the various etiologies that encompass DILI, with unknown factors driving patient susceptibility towards hepatic stress and injury, coupled with the poor concordance of preclinical species to identify human hepatotoxicants in vivo. However, retrospective analysis over the past 50 years has identified several factors associated with DILI that include but are not limited to physicochemical properties of the drug, dose, metabolism and disposition, and signals in a battery of in vitro assays. As such, the pharmaceutical industry and regulatory agencies alike are focused on more comprehensive risk assessment to reduce and/or mitigate DILI risk in drug discovery and early development. This full-day mini-symposium is centered on contemporary perspectives on DILI from an academic, industry, and regulatory perspective, with focused talks addressing mechanisms of DILI, clinical presentation and management, hepatotoxicity risk assessment in drug discovery, and novel tools (including biomarkers) emerging in the field.

Minisymposium topics and speakers:

TBD - William Treem, MD, J&J

The challenges of potential DILI in early clinical development - Michael Rothenberg, MD, PhD, Genentech

Liver Toxicity Knowledge Base – A knowledge base approach for drug-induced liver injury - Weida Tong, PhD, NCTR/FDA

The role of bile acids in DILI and liver diseases - Yazen Alnouti, PhD, University of Nebraska Medical Center (UNMC)

Multi-parametric assessment of hepatotoxicity risk in drug discovery - Donna Dambach, VMD, PhD, Genentech

Reactive metabolites: from assessment to removal in drug discovery - Cyrus Khojasteh, PhD, Genentech

Risk Assessment for Cholestatic Hepatotoxicity: Integrating Transporter Inhibition and FXR Mediated Regulation into a Predictive In Vitro Assay - Kenneth R. Brouwer, PhD, RPh, Qualyst Transporter Solutions

Human Liver Engineering: From Safer Drugs to Liver Regeneration - Gary Peltz, MD, PhD, Stanford University Medical School

.....
WIB Plenary Session, Monday Late Afternoon, June 19, 2017

Event: Plenary Event at BIO Convention: "Pitch Perfect Challenge"

Date and Time: Monday, June 19, 2017, 4:30 p.m. – 7:30 p.m. PST

Location: Manchester Grand Hyatt, 1 Market Place, San Diego, CA 92101

Fees: Member - \$60 and Non Member - \$90

Details and registration at <http://womeninbio.org/eventdetails.aspx?EventId=31272>

On-Line Registration Deadline

Event Description

Inviting. Supporting. Succeeding.

Adjacent the Biotechnology Innovation Organization (BIO) International Convention, please join us for our signature annual WIB Plenary Event on Monday, June 19, 2017, at the beautiful Manchester Grand Hyatt from 4:30 p.m. - 7:30 p.m.

The evening will open with keynote speaker Carol Gallagher, Pharm.D, Partner of New Enterprise Associates, with a presentation discussing the investment landscape and an overview of fund-raising challenges and trends.

We then move into our Pitch Challenge where women leaders in the life sciences will deliver pitches and receive valuable feedback from top female investors on presentation and delivery. If you're up for the Challenge, please apply here by Friday, April 28, 2017. Please complete the application and attach your slide deck in an email to Pitch@womeninbio.org. Participation Eligibility Criteria and Official Rules are listed in the application. Please note that we only review non-confidential materials.

The Pitch Challenge will be moderated by Simone Fishburn, BioCentury Innovations, and our prestigious panel of judges include:

- Nina Kjellson, Caanan Ventures
- Margarita Chavez, AbbVie Ventures
- Kristina Burow, ARCH Partners
- Heather Behanna, Sofinnova
- Marianne De Backer, Johnson & Johnson
- Carol Gallagher, NEA

As with all Women In Bio events, our Plenary Event encompasses an inviting and fun environment for networking as it brings together people from all corners of the life sciences industry, and spawns new career and business opportunities.

This event is not to be missed so register today!

JLABS, Tuesday Morning, June 20, 2017

Event: "Meet with... Novartis Venture Fund"

Date and Time: Tuesday, June 20, 2017 from 10:30 AM to 1:00 PM (PDT)

Agenda:

9:00 AM | Registration, Breakfast, and Networking
9:30 AM | Components of a collaboration agreement
10:00 AM | Panel Discussion: Implications of Components
11:00 AM | Q&A
11:30 AM | Program Close

*Companies must have applied for a one-on-one meeting ahead of time and been approved. Applications are due May 19, 2017. [Apply Here.](#)

Location: JLABS @ SSF, 329 Oyster Point Blvd - 3rd Floor, South San Francisco, California

Ticket Information

Fees:

Presentation

\$25 | General Public

\$35 | Onsite

Includes presentation, Q&A, and lunch. All attendees must pay this fee, regardless of one-on-one meeting status. Pre-registration to attend the presentation, Q&A, and lunch will remain open until noon on June 20 (or sold out).

One-on-One Meeting

FREE | Application

FREE | Accepted Companies

Apply to meet one-on-one with representatives from Novartis Venture Fund. Your application will be reviewed and you will be notified of acceptance on Monday June 6, 2017. Acceptance of a one-on-one meeting is not guaranteed as all applications must be approved.

Event Details

Let's get more solutions to patients. The Johnson & Johnson Innovation, JLABS (JLABS) Meet with... Series helps life sciences entrepreneurs, as well as the academic community, connect with potential partners including corporate venture, VC's, Angels and other investment entities.

On June 20th Principal Christine Brennan and Life Sciences Investment and Operations Professional Giovanni Ferrara of the Novartis Venture Fund (NVF) team will be in attendance to give an overview presentation about the fund's key areas of interest and to meet 1-on-1 with companies that have been accepted after applying online.

Program Overview:

The Novartis Venture Fund founded in 1996, currently manages over \$750 Million in committed capital, and has investments in ~40 portfolio companies globally. NVF's strategy is to build a diverse portfolio of life science companies, across:

Biotechnology/biopharma

Medical device/diagnostics

Digital/eHealth

NVF is stage agnostic and engages in seed investments as well as later-stage investments, typically investing up to \$15 - \$20 million over the life of the company. In investing, NVF looks for unmet need and clinical impact, novel proprietary science and understanding of mechanism, management and board experience and capital efficiency.

Following the presentation, don't miss this opportunity to introduce yourself to the team during the networking lunch. And finally, for those companies who apply online and are approved, one-on-one meetings with Novartis Venture Fund will provide an intimate forum to discuss your company

Speaker Bios:

Christine Brennan | Principal, Novartis Venture Fund

Dr. Brennan joined the Novartis Venture Fund in November 2013. Prior to joining Novartis Venture Fund, Dr. Brennan spent 3 years at Vitae Pharmaceuticals as Chief Business Officer responsible for strategy & business development. Prior to Vitae, she spent 5 years at Novartis Institutes for BioMedical Research in Strategic Alliances, most recently as Executive Director and Head of Strategy & Operations. Prior to Novartis, she held positions in business development and marketing at the biopharmaceutical companies, EnVivo Pharmaceuticals (now FORUM Pharmaceuticals), Biovail (now Valeant Pharmaceuticals) and Cogent Neuroscience. In addition, she was Director at Fidelity Biosciences Group (now F-Prime Capital Partners), a venture capital company. She received her Ph.D. in neuroscience from Dartmouth Medical School in 1995 and completed a postdoctoral fellowship at the National Institutes of Health in 1999.

Giovanni Ferrara | Life Sciences Investment and Operations Professional, Novartis Venture Fund